Matches in Wikidata for { <http://www.wikidata.org/entity/Q93215051> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q93215051 description "clinical trial" @default.
- Q93215051 description "ensayo clínico" @default.
- Q93215051 description "ensayu clínicu" @default.
- Q93215051 description "klinisch onderzoek" @default.
- Q93215051 description "клінічне випробування" @default.
- Q93215051 description "临床试验" @default.
- Q93215051 name "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 name "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 type Item @default.
- Q93215051 label "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 label "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 prefLabel "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 prefLabel "Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults" @default.
- Q93215051 P1050 Q93215051-EE0048C9-8DD8-4A2F-8366-17299F96DC3D @default.
- Q93215051 P1132 Q93215051-8475E132-206A-467E-A352-00268D0F652A @default.
- Q93215051 P1476 Q93215051-BA11597A-0E87-4846-9E5A-68F203E8A56D @default.
- Q93215051 P1813 Q93215051-1EC7D17D-A026-40FE-B68A-24EFF64CC740 @default.
- Q93215051 P2899 Q93215051-71F367E7-24E5-4B36-A2C4-6C4243DF69F1 @default.
- Q93215051 P3098 Q93215051-0ACCD84D-CEEC-4CB5-9ED3-97A98FC1E998 @default.
- Q93215051 P31 Q93215051-01608DDE-3988-400E-9CAC-8D13592D2E37 @default.
- Q93215051 P4135 Q93215051-296BC215-5FCF-496C-89FD-F013256A2644 @default.
- Q93215051 P4844 Q93215051-BE22BA01-97C1-4501-BA09-A3B1611F9962 @default.
- Q93215051 P580 Q93215051-D92468E1-9440-4992-9FDC-4C643257C713 @default.
- Q93215051 P582 Q93215051-1BF32F58-54B1-4BB8-8877-E2214933FE29 @default.
- Q93215051 P6099 Q93215051-747D3324-6A74-44DD-92F8-8AB73BC764A7 @default.
- Q93215051 P8005 Q93215051-E699D2F5-3B60-4A88-A4E3-E2F427899ECD @default.
- Q93215051 P8363 Q93215051-F0A91223-D7F0-4AF8-8675-77C93A4B0961 @default.
- Q93215051 P859 Q93215051-979647A1-46B7-4CBC-8082-88B47B899F62 @default.
- Q93215051 P921 Q93215051-2B184A5B-F5A2-4346-BCE6-F63C4EC2E9E7 @default.
- Q93215051 P921 Q93215051-E7612618-61FF-4595-85F1-D47DF10082EF @default.
- Q93215051 P1050 Q2092064 @default.
- Q93215051 P1132 "+63" @default.
- Q93215051 P1476 "Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)" @default.
- Q93215051 P1813 "AFFINE" @default.
- Q93215051 P2899 "+18" @default.
- Q93215051 P3098 "NCT04370054" @default.
- Q93215051 P31 Q30612 @default.
- Q93215051 P4135 "+64" @default.
- Q93215051 P4844 Q20801759 @default.
- Q93215051 P580 "2020-07-15T00:00:00Z" @default.
- Q93215051 P582 "2022-08-12T00:00:00Z" @default.
- Q93215051 P6099 Q42824827 @default.
- Q93215051 P8005 Q76649614 @default.
- Q93215051 P8363 Q78089383 @default.
- Q93215051 P859 Q206921 @default.
- Q93215051 P921 Q134003 @default.
- Q93215051 P921 Q57136618 @default.